The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action. Antipsychotic drug development has been a slow process since the discovery of chlorpromazine more than 45 years ago. Researchers identify a large number of potential compounds screen them for antipsychotic activity in in vitro and animal test models